Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
Law AMK, Valdes-Mora F, Gallego-Ortega D. · 2020
Read Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. by Law AMK, Valdes-Mora F, Gallego-Ortega D. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7140518.txt.
Introduction
Law, Valdes-Mora, and Gallego-Ortega review myeloid-derived suppressor cells as a cancer treatment target, in Cells. These immature immune cells accumulate in cancer and shut down T cells and natural killer cells. That suppression helps tumors grow, prepares sites for spread, and blunts immunotherapy.
Checkpoint inhibitor drugs have transformed some cancers, yet many patients gain little, and suppressor cells are one reason why. The review describes how these cells are identified, how they expand, and what they do. Current ways to attack them are surveyed, alone and combined with checkpoint therapy. Removing their brake on immunity, the authors argue, could raise the share of patients who benefit from immunotherapy.
Catalog record
| CREATOR | Law AMK, Valdes-Mora F, Gallego-Ortega D. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 97 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer By Andrew M K Law, Fatima Valdes-Mora, David Gallego-Ortega Published in: Cells DOI: 10.3390/cells9030561 ABSTRACT Abstract The emergence of immunotherapy has been an astounding breakthrough in cancer treatments. In particular, immune checkpoint inhibitors, targeting PD-1 and CTLA-4, have shown remarkable therapeutic outcomes. However, response rates from immunotherapy have been reported to be varied, with some having pronounced success and others with minimal to no clinical benefit. An important aspect associated with this discrepancy in patient response is the immune-suppressive effects elicited by the tumour microenvironment (TME). Immune suppression plays a pivotal role in regulating cancer progression, metastasis, and reducing immunotherapy success. Most notably, myeloid-derived suppressor cells (MDSC), a heterogeneous population of immature myeloid cells, have potent mechanisms to inhibit T-cell and NK-cell activity to promote tumour growth, development of the pre-metastatic niche, and contribute to resistance to immunotherapy. Accumulating research indicates that MDSC can be a therapeutic target to alleviate their pro-tumourigenic functions and immunosuppressive activities to bolster the efficacy of checkpoint inhibitors. In this review, we provide an overview of the general immunotherapeutic approaches and discuss the characterisation, expansion, and activities of MDSCs with the current treatments used to target them either as a single therapeutic target or synergistically in combination with immunotherapy. Keywords: Myeloid derived suppressor cells, tumour microenvironment, immunotherapy, immune system, immune checkpoint inhibitors 1. INTRODUCTION The immune system is a complex and dynamic system that operates through an intricate network of cellular interactions and transient functional states. It is involved in various biological activities and is the sine qua non for natural defense of the human body against pathological processes. In cancer progression, the immune system plays a pivotal role where immune cells infiltrate tumours, co-evolving and cooperating with cancer cells to create an inflammatory and immunosuppressive microenvironment to facilitate tumour growth and dissemination. In the early stages of carcinogenesis, immunologically vulnerable neoplasms are contained and abrogated by immune cells upon detection by immunosurveillance, a process where the immune system inhibits aberrant cell growth. The elimination of immunogenic neoplasms creates a selective pressure that drives the propagation of non-immunogenic clones with adapted mechanisms for immune evasion and survival. Paradoxically the immunosurveillance process against tumour cells promotes the immunoselection of poorly immunogenic variants. The continuous cycle of immune selection for resistant cancer variants leads to tumour escape through multiple mechanisms, including reduced expression of tumour-associated antigens and co-stimulatory molecules, including major histocompatibility complex (MHC) [1]. Tumour cells can also hijack mechanisms that confer survival advantages by increasing proliferation and/or reducing apoptosis [2]. This paradigm of cancer “immunoediting” describes the evolution and selection of cancer cells to develop clinically relevant tumours. The development, survival, and spread of cancer cells involve a myriad of complex interactions between cancer and immune cells; in which immune cells are involved in both pro-tumourigenic and anti-tumourigenic roles [3,4,5,6]. The diverse immune milieu that exists within the tumour microenvironment (TME) secretes various signals that orchestrate the development and progression of cancer through the selection of pro-tumourigenic characteristics such as bypassing apoptotic pathways, immunoevasion, and maintaining inflammation and angiogenesis [3]. As the TME develops and evolves, immunosuppressive cells such as T-regulatory cells (Treg) and myeloid derived suppressor cells (MDSCs) are co-opted to inhibit the proliferation and activity of killer T cells; thereby promoting tumour progression and metastasis. On the other hand, the immune system can be stimulated to elicit an immune response that targets the tumour for eradication. Thus, the main theory of immunotherapy resides on the plasticity of the immune system and its capacity to be re-educated into restoring a potent anti-tumourigenic response. Thus, immunosuppressive cells within the TME have become a major target for improving the efficacy of immunotherapy, and multiple therapeutic strategies have been developed in the last few years. In this review, we examine the phenotypic characteristics of MDSCs, their immunosuppressive functions and the mechanisms they employ to suppress anti-tumour response, how a pro-inflammatory TME drives MDSC expansion, and current treatments that are used to target MDSCs. Finally we discuss the synergistic treatments of combining immune checkpoint inhibitors with MDSC targeting. 2. IMMUNOTHERAPY AGAINST CANCER Over the last few years, there has been increasing interest in developing cancer therapeutics that target different aspects of the immune system. With the common aim of re-educating or re-activating the immune milieu to produce a potent immune rejection of cancer cells, different strategies have been established or are under intense development. 2.1. Cancer Vaccines Cancer vaccines are generated using different approaches. They are accomplished by exposure to cancer cells, cell lysates, RNA/DNA, or engineered-viral tumour antigens, but most commonly developed through tumour-associated antigens (TAA) [7,8]. These vaccines can be used for prevention—such as the FDA-approved hepatitis B virus (HBV) vaccine for liver cancer and human papillomavirus (HPV) vaccine for cervical cancer [9,10]—or therapeutically to regulate the progression of existing tumours. TAA are often used in cancer vaccine development and can be primarily characterised as either (i) differentiation antigens: tissue-specific proteins that are expressed in the tumour and the analogous normal tissue, but are aberrantly expressed in the tumour due to hyperproliferation of particular cell type (e.g. PAP); or (ii) overexpressed antigens: highly expressed proteins in tumours due to malignancy, but have a baseline expression in healthy tissue (e.g. Her2/neu) [11,12]. As such, the TAA selected for the vaccine is critical to ensure appropriate specificity and induction of T-cell activity against the antigen in tumours [13]. Unfortunately therapeutic vaccines have not demonstrated as successful clinical efficacy as other immunotherapy efforts such as CAR T-cell therapy or checkpoint inhibitors [14]. This poor outcome can be attributed to diverse antigen expressions due to tumour heterogeneity, low levels of tumour-infiltrated lymphocytes (TILs), and the evolution of different immunosuppressive mechanisms that have developed over the course of the cancer progression. Dampening the immune response through expansion of immunosuppressive cells, expression of inhibitory cytokines and proteins, and angiogenesis have all contributed to the disappointing clinical result [14,15]. 2.2. Monoclonal Antibodies Similar to cancer vaccines, monoclonal antibodies target specific antigens dysregulated in cancer cells to either elicit an immune response against the tumour or for direct drug delivery [16]. The monoclonal antibodies can be unconjugated, conjugated with chemotherapy or radiolabelled, or bispecific [8,17]. Unconjugated antibodies mark cancer cells for immune destruction and can also be used to inhibit antigen functions; for example, targeting HER2 overexpression by Trastuzumab in the treatment of breast cancer can reduce cancer cell proliferation via HER2 degradation and induce antibody-dependent cellular cytotoxicity [18,19]. 2.3. Adoptive T cell Therapy Adoptive cell therapy (ACT) enhances anti-tumour rejection by infusing patients with enriched and modified T cells via two primary methods: i) expanding isolated TILs or ii) genetic modification of peripheral blood T cells to enhance tumour cell recognition (Figure 1) [20]. [Figure: Workflow of adoptive T-cell therapy using TILs or receptor modified T-cells. Adoptive T-cell therapy can improve anti-tumour response by expanding TIL populations extracted from patient tumour (left), or genetically modifying the TCR or generating a chimeric antigen receptor (CAR) (right). With TIL expansion, the patient tumour is surgically resected and the TILs are isolated and expanded ex vivo. The TIL populations are then further increased through a Rapid Expansion Protocol before they are intravenously infused back into the lymphodepleted